Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 668

1.

A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.

Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT.

Mol Endocrinol. 2005 Jun;19(6):1593-605. Epub 2005 Apr 14.

PMID:
15831517
2.

LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.

Gilardi F, Giudici M, Mitro N, Maschi O, Guerrini U, Rando G, Maggi A, Cermenati G, Laghezza A, Loiodice F, Pochetti G, Lavecchia A, Caruso D, De Fabiani E, Bamberg K, Crestani M.

J Biol Chem. 2014 Mar 7;289(10):6908-20. doi: 10.1074/jbc.M113.506394. Epub 2014 Jan 22.

3.

Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.

Kasai S, Inoue T, Yoshitomi H, Hihara T, Matsuura F, Harada H, Shinoda M, Tanaka I.

J Pharmacol Sci. 2008 Sep;108(1):40-8. Epub 2008 Sep 6.

4.

AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.

Schäfer HL, Linz W, Falk E, Glien M, Glombik H, Korn M, Wendler W, Herling AW, Rütten H.

Acta Pharmacol Sin. 2012 Jan;33(1):82-90. doi: 10.1038/aps.2011.165.

5.

Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.

Kanda S, Nakashima R, Takahashi K, Tanaka J, Ogawa J, Ogata T, Yachi M, Araki K, Ohsumi J.

J Pharmacol Sci. 2009 Oct;111(2):155-66. Epub 2009 Oct 6.

6.
7.

Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.

Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM.

Biochem Biophys Res Commun. 2005 Oct 28;336(3):747-53.

PMID:
16157299
8.

Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.

Tanabe J, Tamasawa N, Yamashita M, Matsuki K, Murakami H, Matsui J, Sugimoto K, Yasujima M, Suda T.

Diabetes Obes Metab. 2008 Sep;10(9):772-9. Epub 2007 Oct 26.

PMID:
17970759
9.

Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.

Choi WS, Lee JJ, Kim Y, Kim IS, Zhang WY, Myung CS.

Arch Pharm Res. 2011 Apr;34(4):615-24. doi: 10.1007/s12272-011-0412-9. Epub 2011 May 5.

PMID:
21544727
10.

The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

Seber S, Ucak S, Basat O, Altuntas Y.

Diabetes Res Clin Pract. 2006 Jan;71(1):52-8. Epub 2005 Jul 11.

PMID:
16009445
11.

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

Eur J Pharmacol. 2008 Apr 14;584(1):192-201. doi: 10.1016/j.ejphar.2007.12.036. Epub 2008 Feb 14.

PMID:
18346728
12.

A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.

Jeong HW, Lee JW, Kim WS, Choe SS, Kim KH, Park HS, Shin HJ, Lee GY, Shin D, Lee H, Lee JH, Choi EB, Lee HK, Chung H, Park SB, Park KS, Kim HS, Ro S, Kim JB.

Diabetes. 2011 Feb;60(2):496-506. doi: 10.2337/db09-1145.

13.

Pharmacological profile of a novel, non-TZD PPARgamma agonist.

Chen X, Osborne MC, Rybczynski PJ, Zeck R, Yang M, Xu J, Zhou L, Cryan E, Tang Y, Demarest KT.

Diabetes Obes Metab. 2005 Sep;7(5):536-46.

PMID:
16050946
14.

KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.

Konda VR, Desai A, Darland G, Grayson N, Bland JS.

PLoS One. 2014 Jan 30;9(1):e87848. doi: 10.1371/journal.pone.0087848. eCollection 2014.

15.

PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.

Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY.

Eur J Pharmacol. 2008 Oct 24;595(1-3):119-25. doi: 10.1016/j.ejphar.2008.07.066. Epub 2008 Aug 12.

PMID:
18727927
16.

P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.

Chen W, Zhou XB, Liu HY, Xu C, Wang LL, Li S.

Br J Pharmacol. 2009 Jul;157(5):724-35. doi: 10.1111/j.1476-5381.2009.00231.x. Epub 2009 May 5.

17.

Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.

Chakrabarti R, Misra P, Vikramadithyan RK, Premkumar M, Hiriyan J, Datla SR, Damarla RK, Suresh J, Rajagopalan R.

Eur J Pharmacol. 2004 May 3;491(2-3):195-206.

PMID:
15140637
18.

PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.

Hulsmans M, Geeraert B, Arnould T, Tsatsanis C, Holvoet P.

PLoS One. 2013 Apr 19;8(4):e62253. doi: 10.1371/journal.pone.0062253. Print 2013.

19.

Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice.

Park MH, Park JY, Lee HJ, Kim DH, Park D, Jeong HO, Park CH, Chun P, Moon HR, Chung HY.

PLoS One. 2013 Nov 14;8(11):e78815. doi: 10.1371/journal.pone.0078815. eCollection 2013.

20.

Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.

Park SY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY, Hong KW.

J Pharmacol Exp Ther. 2009 May;329(2):571-9. doi: 10.1124/jpet.108.146456. Epub 2009 Feb 12.

Supplemental Content

Support Center